In accordance with the previously conducted computational analyses that predicted MortaparibPlus binding to mortalin, but not p53 [31], co-immunoprecipitation analyses were performed to immunoprecipitate equal amounts of mortalin complexes from the control and MortaparibPlus-treated breast cancer cell lysates. Here, TP53 is linked to breast cancer.